The deal covers certain IP developed by Mayo Clinic cardiologists Henna Kalsi, M.D., and Thom W. Rooke, M.D.; and engineers Alex Streeter, Raymond Phelps and James H. Christensen. Amsel Medical intends to incorporate the licensed IP in the development of its Occluder device, designed for use on tubular structures or blood vessels between 2 mm and 7 mm that need a metal ligating clip.
Earlier this year, Amsel Medical filed a pre-market notification (510(k)) with the U.S. Food and Drug Administration (FDA) for the Occluder device.
“We are thrilled to collaborate with the Mayo Clinic as we continue the development of the Amsel Occluder device. A fundamental part of our strategy rests upon assembling broad-based intellectual property protections for our development efforts," said Amsel Medical President/Founder Arnold Miller, M.D. "The signing of this patent license agreement is a key component of that strategy. We anticipate significant clinical interest for this innovative technology in the markets where the Amsel Occluder will be cleared for commercial distribution.”
The Amsel Occluder device is designed to easily and securely close blood vessels (veins or arteries as well as hollow ducts) during surgical procedures. The product employs a proprietary mechanical design that enables a vessel clamp to be introduced during open surgery. The Occluder device transfixes the target vessel with the clamp to provide closure.
Celebrating its 150 anniversary in 2014, Mayo Clinic is a nonprofit medical practice and medical research group based in Rochester, Minn.
Amsel Medical Corporation, a development stage medical device company, founded in 2011, is developing the Amsel Occluder device intended for simple and secure vessel or duct closure. The company has operations in Cambridge, Mass., and Tel Aviv, Israel. The Amsel Occluder device addresses an estimated 31 million annual U.S. surgical procedures where vessel closure is required.